Comparison of HCV resistance-associated substitutions in patients infected with HCV genotype 3 before and after failure to DAA combination therapies

Conference Reports for NATAP

The International Liver Congress™
EASL - European Association for the
Study of the Liver
2019 April 10-14
Vienna Austria


Comparison of HCV resistance-associated substitutions in patients infected with HCV genotype 3 before and after failure to DAA combination therapies

	Reported by Jules Levin & EASL 2019 April 10-14 Vienna